Avalo Therapeutics (AVTX) Other Accumulated Expenses (2021 - 2026)
Avalo Therapeutics (AVTX) posted Other Accumulated Expenses of $327000.0 for Q1 2026, little changed on a QoQ basis from $327000.0 in Q4 2025, and little changed year-over-year from $327000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Avalo Therapeutics' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $327000.0 for Q1 2026.
- Quarterly Other Accumulated Expenses changed 0.0% year-over-year to $327000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $327000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses was $327000.0 for Q1 2026 at Avalo Therapeutics, roughly flat from $327000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $607000.0 in Q2 2023 and bottomed at $214000.0 in Q3 2023.
- A 5-year average of $364142.9 and a median of $327000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Peak annual rise in Other Accumulated Expenses reached 115.25% in 2023, while the deepest fall reached 46.37% in 2023.
- Avalo Therapeutics' Other Accumulated Expenses stood at $508000.0 in 2022, then sank by 57.87% to $214000.0 in 2023, then jumped by 52.8% to $327000.0 in 2024, then changed by 0.0% to $327000.0 in 2025, then changed by 0.0% to $327000.0 in 2026.
- Business Quant data shows AVTX's Other Accumulated Expenses at $327000.0 in Q1 2026, $327000.0 in Q4 2025, and $327000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | Avalo Therapeutics | 384.54 Mn | 327.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 327,000.00 |
| Dec 31, 2025 | 327,000.00 |
| Sep 30, 2025 | 327,000.00 |
| Jun 30, 2025 | 327,000.00 |
| Mar 31, 2025 | 327,000.00 |
| Dec 31, 2024 | 327,000.00 |
| Sep 30, 2024 | 241,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 607,000.00 |
| Mar 31, 2023 | 445,000.00 |
| Dec 31, 2022 | 508,000.00 |
| Sep 30, 2022 | 399,000.00 |
| Jun 30, 2022 | 282,000.00 |
| Mar 31, 2022 | 440,000.00 |
| Dec 31, 2021 | 375,000.00 |
| Sep 30, 2021 | 653,000.00 |